Tuesday, 20 Mar 2018

You are here

Sirukumab Turned Down by FDA

On Friday the U.S. Food and Drug Administration announced that will not approve Johnson & Johnson’s rheumatoid arthritis drug sirukumab, stating further data and study would be needed to establish its safety. 

In August, the Arthritis Advisory committee reviewed the company's application and unanimously voted down the approval of sirukumab (13-0), siting concerns about the imbalance in deaths seen for those treated with sirukumab, but not seen with placebo. The most common causes of death were major heart problems, infection and malignancies.

Data showed there were more SAE (serious adverse events) with sirukumab compared to placebo.  As seen with other IL-6 agents, SIR patients demonstrated increased numbers of patients with neutropenia, thrombocytopenia, hyperlipidemia and increased hepatic enzymes (in 44-58%). There were more cases of H.zoster on SIR vs PBO and a few cases of TB and GI perforations on SIR.

The FDA acted upon the recommendation of this subcommittee that noted that while the safety concerns and deaths were difficult to explain, they could not vote in favor of a 3rd IL-6 inhibitor, knowing these safety issues and that two other FDA approved IL-6 inhibitors ( tocilizumab and sarilumab) are commercially available. 

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis

Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.

The US Food and Drug Administration’s (FDA) convened the Gastrointestinal Drugs Advisory Committee Meeting (GIDAC) to assess Pfizers supplemental new drug application for tofacitinib in adult patients with moderately to severely active ulcerative colitis (UC).

Abatacept Efficacy in JIA

Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.

Abatacept Improves GvHD Outcomes

The results from a phase 2 clinical trial presented at the American Society of Hematology meeting demonstrated that the drug abatacept was highly effective in managing severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

Biosimilar Reports - February 2018

Biosimilars command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need.  The global biosimilar market is expected to reach $36 billion USD by 2022. Here is this month's roundup of clinical trials and journal articles, overviews/reviews, practice and physician attitudes, and regulatory and pharma news - all on the subject of biosimilars.

Less Cardiovascular Risk with Abatacept in Rheumatoid Arthritis

A claims data analysis shows that abatacept use in rheumatoid arthritis (RA) patients yielded a modestly reduced cardiovascular risk when compared to patients receiving TNF inhibitors (TNFi).